Less Ads, More Data, More Tools Register for FREE

Pin to quick picksThruvision Grp Regulatory News (THRU)

Share Price Information for Thruvision Grp (THRU)

Share Price is delayed by 15 minutes
Get Live Data
0.725    0.00 (0.00%)
Bid:
0.70
Ask:
0.75
Spread: 0.05 (7.143%)
Market Cap: £3.24m
THRU Live PriceLast checked at - London Stock Exchange

Intraday Thruvision Grp Share Chart

FY26 Trading Update

8 Apr 2026 07:00

RNS Number : 5269Z
Thruvision Group PLC
08 April 2026
 

8 April 2026

 

Thruvision Group plc

 

FY26 Trading Update

 

Thruvision Group plc (AIM: THRU), a leading provider of walk-through security technology ("Thruvision" or the "Company" and, together with its subsidiary undertakings, the "Group"), today announces a trading update for the year ended 31 March 2026 ("FY26").

 

Highlights:

· FY26 revenue has increased by 45% to approximately £6.0 million (FY25: £4.2 million), in line with Board expectations previously communicated in November 2025 of revenue between £5 and £7 million.

· Order backlog at 31 March 2026 was £1.3 million, with order intake for FY26 of £7.1 million. This backlog will be delivered mostly in H1 FY27.

· The Group's cash balance on 31 March 2026 was £2.0 million (31 March 2025: £0.4 million), following a fundraise of £2.6 million, after costs, in July 2025.

 

FY26 revenue grew by £1.8 million or 45% to £6.0 million. This has been underpinned by strong performance in Asia where the award of two material orders totaling £2.7 million formed the bulk of the regional revenue. Our indirect sales strategy in Asia is based on a small number of strong regional partnerships, which we intend to strengthen further over time. The UK and Europe were weaker than FY25, despite strong performance in the Prisons market. Our core market in this region, Retail Distribution, declined due to broader economic conditions, coupled with the ongoing need to rebuild our direct sales capability and regional partnerships. The US grew modestly, due to strong performance from Aviation. Retail Distribution in the US was weaker than expected and we are addressing this with investment in our direct sales force which we expect to lead to a significant improvement in FY27. 

 

Victoria Balchin, CEO, commented: "It's very pleasing to see a return to revenue growth as the steps we have taken to improve both our direct sales force and our partnerships start to take effect. Whilst work remains to be done, our new 81 Series product has been enthusiastically received and the benefits of deploying Thruvision are increasingly appreciated across our markets. Our challenge is now one of investing in our sales and marketing capability and this is the central focus of the team as we start our new year."

 

For further information please contact:

 

Thruvision Group plc

+44 (0)1235 425 400

Tom Black, Executive Chairman

Victoria Balchin, Chief Executive Officer and Chief Financial Officer

Allenby Capital Ltd (Nominated Adviser & Broker)

+44 (0)20 3328 5656

James Reeve

Jos Pinnington / Amrit Nahal (Sales)

 

About Thruvision

Thruvision is a leading international developer, manufacturer and supplier of walk-through security technology. Its technology is deployed in more than 30 countries around the world by government and commercial organisations in a wide range of security situations, where large numbers of people need to be screened quickly, safely and efficiently. Thruvision's patented technology is capable of detecting concealed metallic and non-metallic objects in real time using an advanced AI-based detection algorithm. The Group has offices and manufacturing capabilities in the UK and US.

 

Important information

This announcement may include statements that are, or may be deemed to be, "forward-looking statements" (including words such as "believe", "expect", "estimate", "intend", "anticipate" and words of similar meaning). By their nature, forward-looking statements involve risk and uncertainty since they relate to future events and circumstances, and actual results may, and often do, differ materially from any forward-looking statements. Any forward-looking statements in this announcement reflect management's view with respect to future events as at the date of this announcement. Save as required by applicable law, the Company undertakes no obligation to publicly revise any forward-looking statements in this announcement, whether following any change in its expectations or to reflect events or circumstances after the date of this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTIRMFTMTBMBRF
Date   Source Headline
14th May 20267:00 amRNS-RNew Strategic Partnerships
7th May 202611:45 amRNSBlocklisting cancellation and interim review
7th May 202611:45 amRNSBlocklisting cancellation and interim review
8th Apr 20267:00 amRNSFY26 Trading Update
13th Mar 20267:00 amRNSUS Aviation Contract Award
13th Mar 20267:00 amRNSUS Aviation Contract Award
19th Feb 20267:00 amRNSHolding(s) in Company
19th Feb 20267:00 amRNSContract awards into UK custodial facilities
12th Feb 20267:00 amRNS-RFirst UK “Screening as a Service” Sales
22nd Jan 20267:00 amRNS-RUK Retail Distribution Contract Award
20th Jan 20267:00 amRNSSouth-East Asian Mass Transit Contract Award
12th Jan 20267:00 amRNSHolding(s) in Company
5th Jan 202611:27 amRNSAward of Share Options
19th Dec 20251:07 pmRNS-RUS Retail Distribution Contract Award
19th Dec 20251:07 pmRNS-RUS Retail Distribution Contract Award
16th Dec 20257:00 amRNSHolding(s) in Company
11th Dec 20257:00 amRNSHolding(s) in Company
8th Dec 20257:00 amRNS-RImminent contract award
4th Dec 20257:00 amRNSHolding(s) in Company
28th Nov 20253:45 pmRNSHolding(s) in Company
26th Nov 20257:00 amRNSHolding(s) in Company
25th Nov 20257:00 amRNSInterim Results and Trading Update
6th Nov 20254:30 pmRNSBlock listing Interim Review
6th Nov 20254:30 pmRNSBlock listing Interim Review
23rd Oct 202510:53 amRNSResult of AGM
23rd Oct 20257:00 amRNSAGM Statement and Trading Update
6th Oct 20251:49 pmRNS-RNPSA Testing Update
30th Sep 202512:33 pmRNSHolding(s) in Company
29th Sep 202512:04 pmRNSHolding(s) in Company
29th Sep 202511:26 amRNSDirector/PDMR Shareholding
25th Sep 20257:00 amRNSNotice of AGM
19th Sep 20257:00 amRNSFinal Results
15th Sep 202512:40 pmRNSHolding(s) in Company
9th Sep 20257:00 amRNS-RAdditions to Value-Added Reseller Network
1st Aug 20259:46 amRNSHolding(s) in Company
1st Aug 20257:00 amRNSHolding(s) in Company
31st Jul 20255:00 pmRNSTotal Voting Rights
31st Jul 20252:37 pmRNSHolding(s) in Company
31st Jul 20252:01 pmRNSHolding(s) in Company
31st Jul 202510:32 amRNSHolding(s) in Company
31st Jul 20257:00 amRNSHolding(s) in Company
29th Jul 20251:54 pmRNSHolding(s) in Company
28th Jul 202510:50 amRNSResult of GM and completion of Capital Raising
28th Jul 20257:00 amRNSChange of Adviser
8th Jul 20257:00 amRNSResult of Retail Offer & Notice of General Meeting
4th Jul 20257:05 amRNSWRAP Retail Offer
4th Jul 20257:00 amRNSResult of Review & Proposed Capital Raise
2nd Jul 20257:00 amRNSMaterial Contract Award and Trading Update
23rd Jun 20251:50 pmRNSHolding(s) in Company
23rd Jun 20257:00 amRNSUpdate on Strategic Review and Formal Sale Process

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.